All the news Showing 10 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... European and US regulators approve AbbVie's new combo for all hepatitis C genotypes Liz Highleyman / 08 August 2017 The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV) genotypes 1 to 6, to ... Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Hepatitis C treatment is effective and feasible in Africa Liz Highleyman / 25 July 2017 Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to a presentation yesterday at the ... US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment Liz Highleyman / 19 July 2017 On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ... New pangenotypic hepatitis C drug combinations recommended for approval in the European Union Keith Alcorn / 26 June 2017 Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in next ... Sofosbuvir plus ribavirin cures teens with genotype 2 or 3 hepatitis C Liz Highleyman / 05 June 2017 A two-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course ... Indonesian buyers club helps people obtain generic hepatitis C treatment Liz Highleyman / 30 May 2017 A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high cure rate, according to a ... Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman / 02 May 2017 Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination ... HCV treatment allows one in four people to come off the transplant waiting list Keith Alcorn / 24 April 2017 Around one in four people with hepatitis C and decompensated cirrhosis came off the transplant waiting list in Europe after direct-acting antiviral treatment, and very few had any subsequent liver-related ... ← Prev12345...23Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive